TB-500

evidence score

peptide

Gray Market

180 studies

Thymosin Beta-4TB4Tβ4+1 more

TB-500 is a synthetic form of Thymosin Beta-4, a naturally occurring peptide found in nearly all human cells. It plays a central role in actin sequestration, cell migration, angiogenesis, and wound healing. Research use focuses on accelerating tendon, ligament, and muscle repair, reducing inflammation, and improving flexibility. Evidence comes primarily from animal models and human anecdote. Not approved for human use.

Evidence

Moderate evidence

Safety

Unknown safety profile

Clinical Status

No formal trials

Research Sync

Feb 19, 2026

Dosing

Typical

7.5 mg

2.5 mgRange20 mg

Frequency2x/week (loading 4–6 weeks), then 2–2.5mg 2x/month maintenance

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~4 hours plasma; tissue effects persist days to weeks

Onset1–2 weeks for subjective effects

DurationCumulative over loading phase; maintenance monthly

Routes

subcutaneous

intramuscular

Evidence Score

Level B — Moderate

180 studies indexed

Scoring Factors

Volume(40%)~45/100

Quality(30%)~40/100

Sample Size(10%)~100/100

Consistency(10%)~100/100

Replication(5%)~100/100

Recency(5%)~100/100

Scores estimated from study counts. Exact breakdown computed after research sync.

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

TB-500 is currently categorized as a peptide compound.

Evidence is moderate (64/100): promising signal from 180 indexed studies, but context and population still matter.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Sequesters G-actin, promotes cell migration and angiogenesis via eNOS upregulation and anti-inflammatory cytokine modulation

Practical Context

Strongest current signals

Level C: This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.
Level C: While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides.
Level D: A bioresponsive platform that dynamically interacts with the biological microenvironment to orchestrate multi‐phase bone regeneration, offering new possibilities for complex tissue repair is established.

Elevated caution signals

1 severe/high side effect flag